The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, cilt.25, sa.2, ss.249-253, 2016 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 25 Sayı: 2
- Basım Tarihi: 2016
- Doi Numarası: 10.17219/acem/32484
- Dergi Adı: ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.249-253
- Anahtar Kelimeler: bevacizumab, scleroderma, dermal fibrosis, VEGF, MICROVASCULAR ENDOTHELIAL-CELLS, SYSTEMIC-SCLEROSIS, GROWTH-FACTOR, ANGIOGENESIS, DIFFERENTIATION, PATHOGENESIS, DISEASE, ULCERS
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Ondokuz Mayıs Üniversitesi Adresli: Evet
Özet
Background. The capillary networks are less dense and have irregular structures in scleroderma. These abnormalities result in lower capillary blood flow causing severe tissue hypoxia, which is a major stimulus for angiogenesis. However, current knowledge about compensatory angiogenesis is ambiguous in scleroderma. Bevacizumab is an inhibitor of vascular endothelial growth factor (VEGF).